Réa, Delphine http://orcid.org/0000-0001-5379-7461
Boquimpani, Carla
Mauro, Michael J. http://orcid.org/0000-0002-2251-4032
Minami, Yosuke http://orcid.org/0000-0003-0863-0739
Allepuz, Alex
Maheshwari, Vikalp Kumar
D’Alessio, Denise
Wu, Ying
Lawrance, Rachael http://orcid.org/0000-0002-9499-8443
Narbutas, Sarunas
Sharf, Giora
Hochhaus, Andreas http://orcid.org/0000-0003-0626-0834
Funding for this research was provided by:
Novartis Services Inc., no grant number
Article History
Received: 23 November 2022
Revised: 20 March 2023
Accepted: 22 March 2023
First Online: 14 April 2023
Competing interests
: This study was funded by Novartis Services Inc. DR: honoraria from Novartis (including medical writing support for this current publication), Incyte, and Pfizer. CB: Speakers Bureau for Novartis, Janssen, and Pint Pharma; Board of Directors or advisory committees for Novartis and Janssen. MJM: personal fees from Bristol Myers Squibb, Takeda, and Pfizer. YM: honoraria from Novartis, BMS, Pfizer, and Astellas. AA, DD’A, and YW: employees of Novartis and holders of Novartis stock/shares. VKM: employee of Novartis at the time of conduct of this study. RL: employee of Adelphi Values, a consulting firm that received funding from Novartis to produce this work. SN and GS: Novartis advisory board and steering committee members. AH: research funding from Novartis, Bristol Myers Squibb, Pfizer, and Incyte.